Kraig Biocraft Laboratories Successfully Completes Production Cycle, Delivering Over One Million BAM-1 Alpha Hybrid Eggs for Deployment
Rhea-AI Summary
Kraig Biocraft Laboratories (OTCQB: KBLB) completed a production cycle delivering more than one million BAM-1 Alpha hybrid eggs on Dec. 15, 2025. The eggs are staged for release over the next quarter to support recombinant spider silk production.
The company says BAM-1 Alpha provides greater uniformity, resiliency, throughput and consistency, enabling an accelerated 6-month production schedule and supporting expansion initiatives in Southeast Asia.
Positive
- Production milestone: >1,000,000 BAM-1 Alpha eggs completed
- Operational gains: improved throughput and consistency reported
- Commercial rollout support: aggressive 6-month production schedule
- Geographic expansion: capacity enables Southeast Asia expansion initiatives
Negative
- None.
Breakthrough hybrid line continues to demonstrate superior resilience and scalability as the Company advances major production expansion initiatives
ANN ARBOR, Mich., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the successful completion of its most recent production cycle, yielding more than one million BAM-1 Alpha hybrid eggs. These eggs are now staged for release over the next quarter and will serve as the next wave of recombinant spider silk production.
This milestone marks another decisive validation of the Company's strategic transition to this more advanced spider silk line. The BAM-1 Alpha line has delivered greater uniformity and significantly greater resiliency throughout every phase of the production process. These gains directly translate into improved throughput, consistency, and reliability for the Company's expanding spider silk manufacturing platform.
"The success of BAM-1 Alpha is reshaping our production capabilities," said Kim Thompson, Founder and CEO of Kraig Labs. "These results reaffirm the power of this hybrid line, and to surpass the one-million-egg mark so quickly is further evidence that we are scaling efficiently, effectively, and in direct alignment with our commercial objectives."
The rising production capacity enabled by BAM-1 Alpha is also fueling the Company's accelerated expansion initiatives currently underway in Southeast Asia.
"With each new batch, we are strengthening the backbone of our commercial rollout," Thompson continued. "The reliability and robustness of BAM-1 Alpha allow us to move forward quickly with confidence as we expand production."
The Company has developed an aggressive production schedule for the next 6 months based on these exciting results and is already putting that plan into action.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
FAQ
What did Kraig Biocraft Laboratories (KBLB) announce on December 15, 2025?
How will the one million BAM-1 Alpha eggs affect KBLB production in Q1 2026?
What operational improvements did Kraig Labs report for the BAM-1 Alpha line?
Is Kraig Labs expanding production geographically after the BAM-1 Alpha results?
Where can investors watch Kraig Labs' recent investor conference and updates?
